Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
NEW YORK (Reuters Health) – For pregnant women who require chronic anticoagulation, low molecular weight heparin (LMWH) is an alternative to warfarin, but not an ideal one, according…
NEW YORK (Reuters Health) – In an update to its 2003 guidelines for stage IV non-small-cell lung cancer (NSCLC) chemotherapy, the American Society of Clinical Oncology (ASCO) recommends…
ORLANDO (Reuters Health) – In a head-to-head comparison, extended-release niacin outperformed ezetimibe in shrinking carotid intima-media thickness in patients who were already taking statins, raising yet another red…
NEW YORK (Reuters Health) – Anti-tumor necrosis factor (TNF) agents do not increase the risk of cancer during the first few years of use for rheumatoid arthritis, according…
NEW YORK (Reuters Health) – The initial empiric antimicrobial therapy used to treat septic shock may be the most important determinant of whether a patient will survive to…
NEW YORK (Reuters Health) – Because cholinesterase inhibitors induce can bradycardia, particularly at higher doses, physicians are being urged to closely monitor patients treated with these medications, especially…
NEW YORK (Reuters Health) – New research indicates that tenofovir 300 mg-emtricitabine 200 mg (TDF-FTC) is comparable to abacavir 600 mg-lamivudine 300 mg (ABC-3TC) in anti-HIV efficacy but…
NEW YORK (Reuters Health) – Use of erythropoiesis-stimulating agents in US cancer patients undergoing chemotherapy has increased 10-fold since their introduction, yet there’s been no associated decline in…
NEW YORK (Reuters Health) – Long-term ambrisentan therapy safely improves exercise capacity in patients with pulmonary arterial hypertension (PAH), according to results of an extension protocol that followed…
NEW YORK (Reuters Health) – In patients with locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN), the survival benefit of adding cetuximab to radiotherapy is still…
